Celltrion (068270) Q2 2025 earnings summary

Executive summary

• Achieved record-high quarterly operating profit since merger, driven by a shift to high-margin products and operational efficiencies.

• Biologics sales grew 14.1% year-over-year, with young products more than doubling and now comprising 53% of sales.

• Non-biologics sales declined due to the transfer of Takeda's primary care business, but profitability impact was limited.

Financial highlights

• 2Q25 sales reached KRW 961.5B, up 9.9% year-over-year and 14.2% sequentially.

• Operating profit surged 234.5% year-over-year to KRW 242.5B, with OP margin expanding to 25.2%.

• Gross profit margin improved to 56.6% in 2Q25 from 42.1% in 2Q24.

• Net profit for 2Q25 was KRW 63B, with a net profit margin of 6.6%.

• High-margin young products drove both revenue and profit growth.

Outlook and guidance

• Young portfolio expected to exceed 60% of full-year sales in 2025.

• Five new biosimilar launches planned by end of 2025, expanding addressable market from $55B to $103B.

• Further COGS ratio improvement anticipated as new products expand and R&D amortization ends.